Methods for intraluminal local drug delivery
Devices, systems for localized delivery of a chemotherapy, hormonal therapy or targeted drug/biologic therapy to a target tissue area of an internal body organ of a patient. A catheter 10 forms a sealed treatment chamber in a natural lumen extending through the target tissue area. Air is purged from the chamber, which is then filled with a liquid drug solution for an adequate treatment session time, solution volume and drug concentration to saturate the target tissue area, thereby providing the treatment. The liquid drug solution may be circulated or recirculated through the chamber or maintained stationary therewithin. The drug may saturate the target tissue area and pass therethrough into the lymphatic system or interstitial space, which may serve as a reservoir of the drug for continued therapeutic treatment after withdrawal of the catheter. The chamber is evacuated at the end of the treatment session.
1. A method for administering a chemotherapeutic drug to a target tissue in a hollow organ in a subject, comprising:
forming a treatment chamber comprising the target tissue in the hollow organ;
contacting the target tissue in a non-vascular lumen in the hollow organ with a liquid formulation comprising the chemotherapeutic drug, wherein contacting the target tissue with the liquid formulation comprising the chemotherapeutic drug displaces air from the treatment chamber causing the air to be evacuated;
forming a closed-loop fluid circuit; and
maintaining the liquid formulation comprising the chemotherapeutic drug in the closed-loop fluid circuit.
2. The method of claim 1 , wherein the hollow organ is part of a gastrointestinal tract.
3. The method of claim 2 , wherein the hollow organ is a colon.
4. The method of claim 1 , wherein the hollow organ is part of a respiratory tract.
5. The method of claim 4 , wherein the hollow organ is a lung.
6. The method of claim 1 , wherein the hollow organ is part of a female genital tract.
7. The method of claim 6 , wherein the hollow organ is a uterus.
8. The method of claim 1 , wherein the hollow organ is part of a urinary tract.
9. The method of claim 1 , wherein the chemotherapeutic drug is vinblastine, vinorelbine, irinotecan, paclitaxel, docetaxel, epirubicin, doxorubicin, capecitabine, etoposide, topotecan, pemetrexed, carboplatin, fluorouracil, gemcitabine, oxaliplatin, cisplatin, trastuzumab, ramucirumab, bevacizumab or combinations thereof.
10. The method of claim 1 , wherein the chemotherapeutic drug is paclitaxel, cisplatin, or combinations thereof.
11. The method of claim 1 , wherein the chemotherapeutic drug is paclitaxel.
12. The method of claim 1 , wherein the chemotherapeutic drug is cisplatin.
13. The method of claim 1 , wherein a homogenous concentration of the chemotherapeutic drug is maintained in the closed-loop fluid circuit.
14. The method of claim 1 , wherein, following the contacting with the liquid formulation comprising the chemotherapeutic drug, the cancer target tissue is saturated with the chemotherapeutic drug.
15. The method of claim 1 , wherein the liquid formulation comprising the chemotherapeutic drug is circulated in the closed-loop fluid circuit.
16. The method of claim 1 , further comprising a) terminating administration of the chemotherapeutic drug; and b) evacuating the treatment chamber of the liquid formulation after terminating a treatment session.
17. A method for treating a cancer of a hollow organ in a subject, comprising:
forming a treatment chamber comprising a cancer target tissue in the hollow organ;
contacting the cancer target tissue in a non-vascular lumen in the hollow organ with a liquid formulation comprising a chemotherapeutic drug, wherein contacting the target tissue with the liquid formulation comprising the chemotherapeutic drug displaces air from the treatment chamber causing the air to be evacuated;
forming a closed-loop fluid circuit; and
maintaining the liquid formulation comprising the chemotherapeutic drug in the closed-loop fluid circuit.
18. The method of claim 17 , wherein the hollow organ is part of a gastrointestinal tract, a respiratory tract, a female genital tract or a urinary tract.
19. The method of claim 17 , wherein the chemotherapeutic drug is vinblastine, vinorelbine, irinotecan, paclitaxel, docetaxel, epirubicin, doxorubicin, capecitabine, etoposide, topotecan, pemetrexed, carboplatin, fluorouracil, gemcitabine, oxaliplatin, cisplatin, trastuzumab, ramucirumab, bevacizumab or combinations thereof.
20. The method of claim 17 , wherein, following the contacting with the liquid formulation comprising the chemotherapeutic drug, the cancer target tissue is saturated with the chemotherapeutic drug.
21. The method of claim 17 , wherein the liquid formulation comprising the chemotherapeutic drug is circulated in the closed-loop fluid circuit.
22. The method of claim 17 , further comprising a) terminating administration of the chemotherapeutic drug; and b) evacuating the treatment chamber of the liquid formulation after terminating a treatment session.